Advisor Group Holdings Inc. Reduces Stock Position in Pro-Dex, Inc. (NASDAQ:PDEX)

Advisor Group Holdings Inc. cut its stake in shares of Pro-Dex, Inc. (NASDAQ:PDEX) by 13.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 24,660 shares of the medical instruments supplier’s stock after selling 3,894 shares during the period. Advisor Group Holdings Inc. owned about 0.68% of Pro-Dex worth $753,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PDEX. Dimensional Fund Advisors LP raised its position in Pro-Dex by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 52,562 shares of the medical instruments supplier’s stock worth $1,628,000 after acquiring an additional 1,133 shares during the period. Victory Capital Management Inc. purchased a new position in shares of Pro-Dex during the 1st quarter valued at about $1,379,000. BlackRock Inc. grew its stake in shares of Pro-Dex by 2.4% during the 1st quarter. BlackRock Inc. now owns 60,641 shares of the medical instruments supplier’s stock valued at $1,635,000 after acquiring an additional 1,395 shares during the period. Fiera Capital Corp purchased a new stake in Pro-Dex in the 1st quarter worth approximately $323,000. Finally, Geode Capital Management LLC raised its stake in Pro-Dex by 7.5% during the 1st quarter. Geode Capital Management LLC now owns 28,901 shares of the medical instruments supplier’s stock worth $778,000 after acquiring an additional 2,014 shares during the period. 19.87% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:PDEX opened at $26.40 on Friday. The business’s 50-day simple moving average is $28.52 and its two-hundred day simple moving average is $28.94. Pro-Dex, Inc. has a 52 week low of $21.25 and a 52 week high of $42.60. The stock has a market cap of $96.25 million, a PE ratio of 23.57 and a beta of 1.19. The company has a quick ratio of 2.81, a current ratio of 4.10 and a debt-to-equity ratio of 0.57.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Wednesday, August 25th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Pro-Dex had a net margin of 11.70% and a return on equity of 21.42%.

In related news, Director Katrina Marie Kramer Philp bought 3,468 shares of the company’s stock in a transaction that occurred on Monday, September 13th. The stock was purchased at an average price of $24.41 per share, for a total transaction of $84,653.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 40.80% of the stock is currently owned by insiders.

Separately, TheStreet cut shares of Pro-Dex from a “b” rating to a “c+” rating in a research note on Wednesday, August 4th.

Pro-Dex Profile

Pro-Dex, Inc engages in the design, development and manufacture of rotary drive surgical and dental instruments. The firm specializes in medical device and services, industrial and scientific, dental and component, repairs and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding and torque wrenches.

Read More: How Buying a Call Option Works

Want to see what other hedge funds are holding PDEX? Visit to get the latest 13F filings and insider trades for Pro-Dex, Inc. (NASDAQ:PDEX).

Institutional Ownership by Quarter for Pro-Dex (NASDAQ:PDEX)

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with's FREE daily email newsletter.